| BCBS Massachusetts | Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | 2026-07-01 |
| BCBS Massachusetts | Entyvio ( Vedolizumab ) Policy | 2026-07-01 |
| BCBS Massachusetts | Esketamine Nasal Spray (SpravatoTM) and Intravenous Ketamine for Mental Health Conditions | 2026-07-01 |
| BCBS Massachusetts | Extracorporeal Membrane Oxygenation | 2026-07-01 |
| BCBS Massachusetts | GLP-1 and GLP-1 - GIP Agonist Drugs for Anti-Obesity Management and Other Non-Obesity Conditions | 2026-07-01 |
| BCBS Massachusetts | Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Related Drugs for the Treatment of Type 2 Diabetes | 2026-07-01 |
| BCBS Massachusetts | Heart Failure and Hypertrophic Cardiomyopathy (HCM) Policy | 2026-07-01 |
| BCBS Massachusetts | HETLIOZ tasimelteon | 2026-07-01 |
| BCBS Massachusetts | High-Sensitivity C-Reactive Protein | 2026-07-01 |
| BCBS Massachusetts | Hypoactive Sexual Desire Disorder (HSDD) Policy | 2026-07-01 |